The abstract is read at the publisher; the summary is JClub's.
Machine perfusion and multi-omics profiling are positioned to enable real-time, dynamic assessment of donor kidney quality, but most candidate biomarkers remain at discovery or early validation stages.
- Why it matters: Traditional donor scoring has limited predictive capacity, and wider use of marginal-quality organs increases the need for more sophisticated evaluation and better long-term outcome prediction.
- What they did: The work outlines three assessment windows—donor evaluation, during preservation via perfusate/tissue multi-omics sampling, and post-transplant monitoring using donor-derived cell-free deoxyribonucleic acid, urinary chemokines, and advanced imaging.
- The result: Clinical translation is constrained by single-center, small-sample studies, incomplete assay standardization, and a lack of evidence that biomarker-guided decisions improve long-term graft survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.